An open randomised phase II study of gemcitabine plus cisplatin +/- concomitant or sequential ZD1839 [gefitinib] in patients with advanced or metastatic transitional cell carcinoma of the urothelium
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2016
At a glance
- Drugs Cisplatin; Gefitinib; Gemcitabine
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 16 Dec 2007 Status changed from in progress to completed.
- 01 Dec 2005 New trial record.